One night to walk 21km for cancer – 4 December | Last chance!

Improving responsiveness to anti-cancer immunotherapy

Lead researcher

Dr Ashleigh Poh

The Olivia Newton-John Cancer Research Institute

Tumour type:
Colon, Melanoma, Lung

Years funded
(Jul 2017-Jun 2018)

What is the project?

This project exploits expression of the protein Haematopoietic Cell Kinase (HCK) as a novel target to improve the anti-cancer effects of immunotherapy and chemotherapy. The findings from this study will provide important mechanistic insights and pre-cinical proof-of-concept data to support future clinical trials with anti-HCK drugs to reduce tumour growth in patients.

Funding Body

Cancer Council Postdoctoral Fellowship